Get started
Author

Ulrich Jäger

Observed names: U. Jager, U. Jäger, Ulrich Jager, Ulrich Jäger
OpenAlex ID: A5110090697
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation
2007 · S. Choquet, R. Trappe, et al. · Haematologica · 154
PDF
Autoimmune thrombocytopenia in non-Hodgkin's lymphomas
2008 · A. W. Hauswirth, C. Skrabs, et al. · Haematologica · 96
PDF
Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial
2008 · Stephan Stilgenbauer, Thorsten Zenz, et al. · Blood · 43
Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial
2012 · Stephan Stilgenbauer, Raymonde Busch, et al. · Blood · 40
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia
2009 · D. Kienle, A. Benner, et al. · Haematologica · 40
PDF
Endocarditis and Aortal Embolization Caused by Aspergillus terreus in a Patient with Acute Lymphoblastic Leukemia in Remission: Diagnosis by Peripheral-Blood Culture
1998 · G. Schett, B. Casati, et al. · Journal of Clinical Microbiology · 38
PDF
Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).
2004 · Stephan Stilgenbauer, Dirk Winkler, et al. · Blood · 37
Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG
2010 · Thorsten Zenz, Raymonde Busch, et al. · Blood · 32
Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes
2008 · K. Vanura, T. Le, et al. · Haematologica · 25
PDF
TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.
2009 · Thorsten Zenz, Patrick Hoth, et al. · Blood · 15
Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
2008 · Stephan Stilgenbauer, Thorsten Zenz, et al. · Blood · 14
Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia
2007 · A. W. Hauswirth, U. Jager · Haematologica · 14
PDF
Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).
2007 · Stephan Stilgenbauer, Dirk Winkler, et al. · Blood · 14
Blood disorders stepping into the limelight
2016 · U. Jager, C. Chomienne, et al. · Haematologica · 6
PDF
Antibody–Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas
2015 · Ulrich Jager, Martin Hutchings · European Oncology & Haematology · 1
The Use of Brentuximab Vedotin with or without Subsequent Allogeneic Stem Cell Transplantation in Selected Patient Groups
2015 · Ulrich Jager, Felix Keil, et al. · European Oncology & Haematology · 1
PDF
Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)
2012 · Stefan KÖhrer, Greg Coffey, et al. · Blood · 1
Long-term Durable Responses in Patients (pts) With Relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (all), Diffuse Large B-cell Lymphoma (dlbcl), and Follicular Lymphoma (fl) Treated With Tisagenlecleucel (tisa-cel) and Its Association With Persistence of Chimeric Antigen Receptor (car) T Cells
2024 · R. Awasthi, E. Waldron, et al. · Cytotherapy
T2evolve: Standardization of Pre-clinical and Clinical Development of Engineered T Cell Therapy in Europe; a Cross Functional Multi Stakeholder Initiative
2024 · M. Luu, C. Sanges, et al. · Cytotherapy
Combined SNP Microarray Based Genomic Mapping and Next Generation Transcriptome Sequencing Confirms the Presence of Somatic STAT3 Mutations and Identifies Novel Chromosomal Imbalances and Candidate Genes in T Large Granular Lymphocytic Leukemia (T-LGL)
2012 · Patricia Johansson, Ludger Klein-Hitpass, et al. · Blood
Works count: 20
Citation count: 571
H-index: 13
I10-index: 13
Year
Topic
Type